Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the united states and other countries

This publication has 14 references indexed in Scilit:

• A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
  Annals of Oncology, 2002
• Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials
  JNCI Journal of the National Cancer Institute, 2001
• Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
  Journal of Clinical Oncology, 2001
• 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
  Journal of Clinical Oncology, 2000
• Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines
  Journal of Clinical Oncology, 1999
• The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Society of Clinical Oncology survey
  Annals of Oncology, 1999
• Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.
  International Journal of Clinical Pharmacy, 1999
• Erythropoietin Therapy
  New England Journal of Medicine, 1997
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
  Journal of Clinical Oncology, 1994
• Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy
  JNCI Journal of the National Cancer Institute, 1993